Skip to main content
SpringerLink
Log in

Lipidsenkende Mittel

  • Chapter
Arzneiverordnungs-Report 2011

Zusammenfassung

Erhöhte Cholesterinwerte der Low-Density-Lipoproteine (LDL-Cholesterin) gehören zusammen mit arterieller Hypertonie, Diabetes mellitus und Zigarettenkonsum zu den wichtigsten Risikofaktoren kardiovaskulärer Krankheiten. Zahlreiche kontrollierte klinische Studien dokumentieren, dass eine Senkung des LDL-Cholesterinspiegels die Risiken der koronaren Herzkrankheit vermindert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; on behalf of the SHARP Investigators (2011): The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 337: 2181–2192.

    Article  Google Scholar 

  • Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I (2010): Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 31: 1633–1639.

    Article  PubMed  CAS  Google Scholar 

  • Bruckert E, Labreuche J, Amarenco P (2010): Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210:353–361

    PubMed  CAS  Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators (2005): Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

    Article  Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators (2008): Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125.

    Article  Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaboration (2010): Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.

    Article  Google Scholar 

  • Coronary Drug Project (1975): Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381.

    Article  Google Scholar 

  • De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99: 779–785.

    PubMed  Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (2007): Leitlinie Risikoadjustierte Pravention von Herz- und Kreislauferkrankungen. Internet: http://leitlinien.dgk.org/images/pdf/leitlinien_volltext/2007-10_Risikoadjustierte.pdf

  • Drazen JM, Jarcho JA, Morrissey S, Curfman GD (2008): Cholesterol lowering and ezetimibe. N Engl J Med 358: 1507–1508.

    Article  PubMed  CAS  Google Scholar 

  • Erdmann E (2010): Zur aktuellen Debatte über die Senkung des LDL-Cholesterins durch Ezetimib. Dtsch Med Wochenschr 135: 1742.

    Article  PubMed  CAS  Google Scholar 

  • Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004): Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.

    Article  PubMed  Google Scholar 

  • Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group (2002): Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162: 1568–1576.

    Article  PubMed  CAS  Google Scholar 

  • Hayward A, Krumholz H, Zulman DM, Timbie JW, Vijan S (2010): Optimizing statin treatment for primary prevention of coronary artery disease. Ann Int Med 152: 69–77

    PubMed  Google Scholar 

  • Heart Protection Study Collaborative Group (2011): C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469–476.

    Article  Google Scholar 

  • Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML et al (2006): Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295: 655–666.

    Article  PubMed  CAS  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011): Ezetimib bei Hypercholesterinämie – Vorbericht A10-02 (vorläufige Nutzenbewertung). Internet: www.iqwig.de/download/A10-02_Vorbericht_Ezetimib_bei_Hypercholesterinaemie.pdf

  • Jun M, Foote C, Lv L, Neal B, Patel A, Nicholls S, Grobbee DE, Cass A, Chalmers A, Perkovic V (2010): Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875–1884.

    Article  PubMed  CAS  Google Scholar 

  • Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators (2008): Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431–1443.

    Article  PubMed  CAS  Google Scholar 

  • Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TME, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Laatikainen LT, d’Emden MC, Crimet DC, O’Conell RL, Colman PG for the FIELD study investigators (2007): Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 370: 1678–1697.

    Article  Google Scholar 

  • Klose G (2011): Möglichkeiten und Grenzen der modernen Lipidtherapie. Internist 52: 328–335

    Article  PubMed  CAS  Google Scholar 

  • Krumholz HM, Hayward RA (2010): Shifting views on lipid lowering therapy. BMJ 341: 332–333.

    Article  CAS  Google Scholar 

  • Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365–374.

    Article  Google Scholar 

  • Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF (2008): Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62: 1959–1970.

    Article  PubMed  CAS  Google Scholar 

  • Meaney A, Ceballos G, Asbun J, Solache G, Mendoza E, Vela A, Meaney E (2009): The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 49: 838–847.

    Article  PubMed  CAS  Google Scholar 

  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421. http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm

  • National Institute for Health and Clinical Excellence ( 2008): Lipid modification Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease http://www.nice.org.uk/nicemedia/live/11982/40689/40689.

  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005): Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38.

    Article  PubMed  CAS  Google Scholar 

  • NN (2006): Nicotinic acid: new/old drug. Immediate or sustained release: too risky for a drug with no proven benefit. Prescrire Int 15: 213–216.

    Google Scholar 

  • Oberwittler H, Baccara-Dinet M (2006): Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 60: 707–715.

    Article  PubMed  CAS  Google Scholar 

  • Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R (2008): Analyses of cancer data from three ezetimibe trials. N Engl J Med 359:1357–1366.

    Article  PubMed  CAS  Google Scholar 

  • Rajamani K, Colman PG, Ping Li, L, Best JD, Voysey M, d’Emden CD, Laakso, M, John RB on behalf of the FIELD study investigators (2009): Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus ( FIELD study):a prespecified analysis of a randomized controlled trial. Lancet 373: 1780–1788.

    Article  PubMed  CAS  Google Scholar 

  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (2005): C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.

    Article  PubMed  CAS  Google Scholar 

  • Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators (2008): N Engl J Med 359: 1343–1356.

    Article  PubMed  Google Scholar 

  • Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.

    Google Scholar 

  • Schönbeck U, Libby P (2004): Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 (Suppl II): II 18–26.

    Google Scholar 

  • Shaw SM, Fildes JE, Yonan N, Williams SG (2009): Pleiotropic effects and cholesterollowering therapy. Cardiology 112): 4–12.

    Article  PubMed  CAS  Google Scholar 

  • Shepherd J (2002): Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 359: 2271–2273.

    Article  PubMed  Google Scholar 

  • Stevens KK, Jardine AG (2011): SHARP: a stab in the right direction in chronic kidney disease. Lancet 2011 Jun 8 [Epub ahead of print].

    Google Scholar 

  • Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M (2009): Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361: 2113–2122.

    Article  PubMed  CAS  Google Scholar 

  • The ACCORD Study Group (2010): Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.

    Article  Google Scholar 

  • The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102: 21–27.

    Google Scholar 

  • The FIELD study investigators (2005): Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861.

    Article  Google Scholar 

  • Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Hüber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M (2008): Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909–2945.

    Article  PubMed  Google Scholar 

  • Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72-S78.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gemeinschaftspraxis Dres. Thomas Beckenbauer und Stefan Maierhof, Am Markt 11, 28195, Bremen

    Prof. Dr. med. Gerald Klose

  2. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Gerald Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Klose, G., Schwabe, U. (2011). Lipidsenkende Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21992-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21992-4_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21991-7

  • Online ISBN: 978-3-642-21992-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation